AU9655698A - Synthetic genes with immunomodulatory effects - Google Patents
Synthetic genes with immunomodulatory effectsInfo
- Publication number
- AU9655698A AU9655698A AU96556/98A AU9655698A AU9655698A AU 9655698 A AU9655698 A AU 9655698A AU 96556/98 A AU96556/98 A AU 96556/98A AU 9655698 A AU9655698 A AU 9655698A AU 9655698 A AU9655698 A AU 9655698A
- Authority
- AU
- Australia
- Prior art keywords
- synthetic genes
- immunomodulatory effects
- immunomodulatory
- effects
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108700005078 Synthetic Genes Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94902497A | 1997-10-10 | 1997-10-10 | |
| US08949024 | 1997-10-10 | ||
| PCT/SE1998/001801 WO1999019347A1 (en) | 1997-10-10 | 1998-10-06 | Synthetic genes with immunomodulatory effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU9655698A true AU9655698A (en) | 1999-05-03 |
Family
ID=25488491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU96556/98A Abandoned AU9655698A (en) | 1997-10-10 | 1998-10-06 | Synthetic genes with immunomodulatory effects |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU9655698A (en) |
| WO (1) | WO1999019347A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448348C (en) * | 2001-05-25 | 2013-07-16 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| GB0524884D0 (en) * | 2005-12-06 | 2006-01-11 | Syngenta Ltd | Improvements in or relating to organic compounds |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| CN115636870B (en) * | 2022-11-24 | 2024-04-30 | 安徽农业大学 | Cyclic color-threo-valyl-leucinyl peptide with hepatoma cytotoxicity and alpha-glucosidase inhibitory activity and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9325772D0 (en) * | 1993-12-16 | 1994-02-16 | Smithkline Beecham Biolog | Novel compounds |
| SE9403526D0 (en) * | 1994-10-14 | 1994-10-14 | Astra Ab | New Peptides |
| SE9501067D0 (en) * | 1995-03-24 | 1995-03-24 | Astra Ab | New peptides |
| EP0923604A1 (en) * | 1996-04-12 | 1999-06-23 | Astra Aktiebolag | Cysteine-containing or methioine-containing peptides with immunomodulatory effects |
| SE9603463D0 (en) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
-
1998
- 1998-10-06 AU AU96556/98A patent/AU9655698A/en not_active Abandoned
- 1998-10-06 WO PCT/SE1998/001801 patent/WO1999019347A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999019347A1 (en) | 1999-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1709299A (en) | Mixer-injectors | |
| AU8921698A (en) | Follistatin-3 | |
| AU3491897A (en) | Vaccines comprising synthetic genes | |
| AU9414098A (en) | Ascorbyl-phosphoryl-cholesterol | |
| AU2124697A (en) | Synthetic hiv genes | |
| AU6598798A (en) | Resorcinyl-triazines | |
| AU1027499A (en) | 32P-polyphosphazene | |
| AU3380897A (en) | Synthetic hepatitis c genes | |
| AU9513298A (en) | Fluoranthenopyrans | |
| AU8836798A (en) | Synthetic termination | |
| AU5272198A (en) | EMP-charge-eliminator | |
| AU5166296A (en) | New peptides with immunomodulatory effects | |
| AU6998698A (en) | Dioxacycloalkan-8-one | |
| AU4117497A (en) | Micropolarimeter | |
| AU9655698A (en) | Synthetic genes with immunomodulatory effects | |
| AU6417799A (en) | Matrix-remodeling genes | |
| AU6185898A (en) | Clavaspirins | |
| AU6525998A (en) | Improved metallo-endopeptidases | |
| AU8214598A (en) | 3-benzylpiperidine | |
| AU6847598A (en) | Colour legalisation | |
| AU7761998A (en) | Korrosionsschutzanstrichstoff | |
| AU1440097A (en) | Ferromagnetic pigments | |
| AU8991998A (en) | Renovative pipeliner | |
| AU4469997A (en) | Heregulin-gamma | |
| AU5391798A (en) | Thiamacrolides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |